Process for the isolation of 5-Allyl-2-(3,4-dimethoxyphenyl)-3a-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran and pharmaceutical composition for treating inflammatory conditions
申请人:Merck & Co., Inc.
公开号:EP0151687A1
公开(公告)日:1985-08-21
5-allyl-2-(3,4-dimethoxyphenyl)-3α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxabenzofuran and analogs thereof as PAF-antagonists have been isolated from Piper Futokadsura Sieb. et Zucc. and its analogs prepared. These neolignan compounds are found to have potent and specific PAF (Platelet-Activating-Factor) antagonistic activities and are thereby useful in the treatment of various diseases or disorders mediated by the PAF, for example, inflammation, cardiovascular disorder, asthma, lung edema, and adult respiratory distress syndrome.
从 Piper Futokadsura Sieb. et Zucc.中分离出 5-烯丙基-2-(3,4-二甲氧基苯基)-3α-甲氧基-3-甲基-2,3,3a,6-四氢-6-氧杂苯并呋喃及其类似物,并制备出 PAF 拮抗剂。 这些新木质素化合物具有强效和特异的 PAF(血小板活化因子)拮抗活性,因此可用于治疗由 PAF 介导的各种疾病或紊乱,例如炎症、心血管疾病、哮喘、肺水肿和成人呼吸窘迫综合征。